BUY Glenmark Pharmaceuticals — Prakash Gaba, 13 Aug 2026

BUYGlenmark Pharmaceuticals

Glenmark Pharmaceuticals share price target & all analyst calls

byPrakash GabaHorizon: NA (inferred Swing (≤2wk))13 Aug 2026via CNBC Awaaz.

Entry₹2,320Inferred

Target₹2,350

Total upside +1.29%

Stop loss₹2,300-0.86% risk

Exit₹2,30017 Aug 2026, 11:10 am

Stop-loss hit-0.86%

Follow Prakash Gaba for new calls(30% target hit, 295 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 2 active Swing calls on GLENMARK See 150 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 17 Aug 2026

6 supporting4 neutral1 opposing

Supports the BUY call (6)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·14 Aug · 2d ago

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·11 Aug · 5d ago

Glenmark Pharma Q1 Revenue Beats Estimates, EBITDA Margins Seen Rising

NewsGoogle News·4 Aug · 2w ago

Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price

NewsNdtv-Profit·4 Aug · 2w ago

Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth

NewsCnbc-Tv18·31 Jul · 2w ago

Neutral / worth noting (4)

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 5d ago

Glenmark Pharma Q1 FY27 Results and Brokerage Outlook

NewsGoogle News·4 Aug · 2w ago

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·31 Jul · 2w ago

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

BSE · Board Meeting·31 Jul · 2w ago

Weighs against the BUY call (1)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 5d ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Prakash Gaba

Every call and its outcome